Research programme: Ral protein inhibitors - NantBioscience/University of Colorado
Latest Information Update: 17 Sep 2014
At a glance
- Originator NantBioScience; University of Colorado at Denver
- Developer University of Colorado at Denver
- Mechanism of Action Ral GTP-binding protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Sep 2014 Early research in Cancer in USA (unspecified route)